| Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/06 16:05 | prnewswire.com |
| Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 | 10/30 16:05 | prnewswire.com |
| Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough | 10/21 07:30 | prnewswire.com |
| Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences | 10/15 07:30 | prnewswire.com |
| Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program | 10/03 16:05 | prnewswire.com |
| Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D. | 09/30 17:30 | prnewswire.com |
| Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 | 09/26 07:30 | prnewswire.com |
| Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock | 09/06 07:31 | marketbeat.com |
| Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 | 09/04 16:05 | prnewswire.com |
| Trevi Therapeutics to Participate in September Investor and Medical Conferences | 08/28 07:30 | prnewswire.com |